- Home
- RIGL vs AVK Comparison
RIGL vs AVK Comparison
Compare RIGL & AVK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RIGL | AVK |
|---|---|---|
| Founded | 1996 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 564.7M | 551.0M |
| IPO Year | 2000 | 2003 |
Fundamental Metrics
Financial Performance| Metric | RIGL | AVK |
|---|---|---|
| Price | $40.45 | $12.81 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $45.67 | N/A |
| AVG Volume (30 Days) | ★ 386.8K | 124.3K |
| Earning Date | 05-05-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1867.68 | N/A |
| EPS | ★ 0.44 | N/A |
| Revenue | ★ $294,282,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $12.75 | N/A |
| P/E Ratio | $93.09 | ★ N/A |
| Revenue Growth | ★ 64.15 | N/A |
| 52 Week Low | $18.70 | $10.77 |
| 52 Week High | $52.24 | $13.28 |
Technical Indicators
Market Signals| Indicator | RIGL | AVK |
|---|---|---|
| Relative Strength Index (RSI) | 64.43 | 46.70 |
| Support Level | $40.05 | $12.48 |
| Resistance Level | $44.85 | $13.01 |
| Average True Range (ATR) | 1.82 | 0.14 |
| MACD | -0.04 | -0.02 |
| Stochastic Oscillator | 58.00 | 23.81 |
Price Performance
Historical ComparisonAbout RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, REZLIDHIA (olutasidenib), GAVRETO (pralsetinib), R289, and Ocadusertib (Systemic) - Eli Lilly.
About AVK Advent Convertible and Income Fund
Advent Convertible & Income Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in various sectors, such as communications, utilities, energy, industrial, technology, and others.